Dopaminergic Therapy for Anhedonia - 2
Eligible age
25–55 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this 8-week, double-blind, placebo-controlled, study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Seventy male and female participants with depression, between 25-55 years of age, with higher levels of inflammation and anhedonia will be randomized to receive L-DOPA or matched placebo over 8 weeks. Participants will complete lab tests, medical and psychiatric assessments, motivation and motor tasks, and MRI scans as part of the study. The total length of participation is approximately 10 to 12 weeks.
Sponsor: Emory University
You may qualify if…
- ✓ a. willing and able to give written informed consent
- ✓ b. men or women, 25-55 years of age
- ✓ c. a primary diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), current, as diagnosed by the Structured Clinical Interview for DSM-5
- ✓ d. score of \>10 on the Patient Health Questionnaire-9 (PHQ-9) or HAM-D score ≥18
- ✓ e. off all antidepressant or other psychotropic therapy (e.g. mood stabilizers, antipsychotics, anxiolytics, and sedative hypnotics) for at least 4 weeks prior to baseline visit (8 weeks for fluoxetine)
- ✓ f. c-reactive protein (CRP) ≥2 mg/L
- ✓ g. PHQ-9 anhedonia score ≥2
You may not qualify if…
- ✕ a. history or evidence (clinical or laboratory) of an autoimmune disorder
- ✕ b. history or evidence (clinical or laboratory) of hepatitis B or C infection or human immunodeficiency virus infection
- ✕ c. history of any type of cancer requiring treatment with more than minor surgery
- ✕ d. unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination, EKG and laboratory testing)
- ✕ e. history of any (non-mood-related) psychotic disorder; active psychotic symptoms of any type; history or current bipolar disorder; history or current gambling disorder; substance abuse/dependence within 6 months of study entry (as determined by standardized clinician interview)
- ✕ f. active suicidal plan as determined by a score \>3 on item #3 on the HAM-D
- ✕ g. an active eating disorder (except for patients with binge eating disorder in whom binging is clearly associated with worsening of mood symptoms)
- ✕ h. a history of a cognitive disorder or traumatic head injury involving loss of consciousness
Where it's recruiting
Atlanta
Source: ClinicalTrials.gov · NCT06075771 · last updated 2026-01-28